rabbit anti-PKc polyclonal antibody 1035

$100.00 – $2,600.00

Antibody summary

Rabbit polyclonal to PKC (Protein kinase C) alpha
Suitable for: WB, IHC, IP
Reacts with: Hu, Ms presumed rat
Isotype: IgG
100 µg, 25 µg, 1 mg

SKU: 1035parent Categories: antibody, cell marker, oxidative stress Tags: PKC (Protein kinase C) alpha, polyclonal, rabbit

Weight	1 lbs
Dimensions	9 × 5 × 2 in
host	rabbit
isotype	IgG
clonality	polyclonal
concentration	0.2 mg/mL
applications	IHC, IP, WB
reactivity	PKC (Protein kinase C), polyclonal, rabbit
available sizes	1 mg, 100 µg, 25 µg

rabbit anti- pkc polyclonal antibody 1035

antibody
Database link: human P17252 mouse P20444
Tested applications WB, IHC, IP
Recommended dilutions Immunoprecipitation (IP) 20 %micro;l/mg lysate, Western Blot (WB) 1:1000
Immunogen Between 622 and C-terminus
Size and concentration 100µL and 0.2 mg/mL
Form liquid
Storage Instructions Store at 2-8°C. Expires 1 year from date of receipt.
Storage buffer Tris-buffered Saline containing 0.1% BSA and 0.09% Sodium Azide
Purity affinity purified
Clonality polyclonal
Isotype IgG
Compatible secondaries goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863 goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371 goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715 goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control Rabbit polyclonal - Isotype Control

target relevance
Protein names Protein kinase C alpha type (PKC-A) (PKC-alpha) (EC 2.7.11.13)
Gene names PRKCA,PRKCA PKCA PRKACA
Protein family Protein kinase superfamily, AGC Ser/Thr protein kinase family, PKC subfamily
Mass 76750Da
Function FUNCTION: Calcium-activated, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in positive and negative regulation of cell proliferation, apoptosis, differentiation, migration and adhesion, tumorigenesis, cardiac hypertrophy, angiogenesis, platelet function and inflammation, by directly phosphorylating targets such as RAF1, BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and cell growth arrest by positive and negative regulation of the cell cycle. Can promote cell growth by phosphorylating and activating RAF1, which mediates the activation of the MAPK/ERK signaling cascade, and/or by up-regulating CDKN1A, which facilitates active cyclin-dependent kinase (CDK) complex formation in glioma cells. In intestinal cells stimulated by the phorbol ester PMA, can trigger a cell cycle arrest program which is associated with the accumulation of the hyper-phosphorylated growth-suppressive form of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B. Exhibits anti-apoptotic function in glioma cells and protects them from apoptosis by suppressing the p53/TP53-mediated activation of IGFBP3, and in leukemia cells mediates anti-apoptotic action by phosphorylating BCL2. During macrophage differentiation induced by macrophage colony-stimulating factor (CSF1), is translocated to the nucleus and is associated with macrophage development. After wounding, translocates from focal contacts to lamellipodia and participates in the modulation of desmosomal adhesion. Plays a role in cell motility by phosphorylating CSPG4, which induces association of CSPG4 with extensive lamellipodia at the cell periphery and polarization of the cell accompanied by increases in cell motility. During chemokine-induced CD4(+) T cell migration, phosphorylates CDC42-guanine exchange factor DOCK8 resulting in its dissociation from LRCH1 and the activation of GTPase CDC42 (PubMed:28028151). Is highly expressed in a number of cancer cells where it can act as a tumor promoter and is implicated in malignant phenotypes of several tumors such as gliomas and breast cancers. Negatively regulates myocardial contractility and positively regulates angiogenesis, platelet aggregation and thrombus formation in arteries. Mediates hypertrophic growth of neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-dependent signaling pathway, and upon PMA treatment, is required to induce cardiomyocyte hypertrophy up to heart failure and death, by increasing protein synthesis, protein-DNA ratio and cell surface area. Regulates cardiomyocyte function by phosphorylating cardiac troponin T (TNNT2/CTNT), which induces significant reduction in actomyosin ATPase activity, myofilament calcium sensitivity and myocardial contractility. In angiogenesis, is required for full endothelial cell migration, adhesion to vitronectin (VTN), and vascular endothelial growth factor A (VEGFA)-dependent regulation of kinase activation and vascular tube formation. Involved in the stabilization of VEGFA mRNA at post-transcriptional level and mediates VEGFA-induced cell proliferation. In the regulation of calcium-induced platelet aggregation, mediates signals from the CD36/GP4 receptor for granule release, and activates the integrin heterodimer ITGA2B-ITGB3 through the RAP1GAP pathway for adhesion. During response to lipopolysaccharides (LPS), may regulate selective LPS-induced macrophage functions involved in host defense and inflammation. But in some inflammatory responses, may negatively regulate NF-kappa-B-induced genes, through IL1A-dependent induction of NF-kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1, which modulates EIF4G1 binding to MKNK1 and may be involved in the regulation of EIF4E phosphorylation. Phosphorylates KIT, leading to inhibition of KIT activity. Phosphorylates ATF2 which promotes cooperation between ATF2 and JUN, activating transcription. Phosphorylates SOCS2 at 'Ser-52' facilitating its ubiquitination and proteasomal degradation (By similarity). Phosphorylates KLHL3 in response to angiotensin II signaling, decreasing the interaction between KLHL3 and WNK4 (PubMed:25313067). {ECO:0000250\|UniProtKB:P20444, ECO:0000269\|PubMed:10848585, ECO:0000269\|PubMed:11909826, ECO:0000269\|PubMed:12724315, ECO:0000269\|PubMed:12832403, ECO:0000269\|PubMed:15016832, ECO:0000269\|PubMed:15504744, ECO:0000269\|PubMed:15526160, ECO:0000269\|PubMed:18056764, ECO:0000269\|PubMed:19176525, ECO:0000269\|PubMed:21576361, ECO:0000269\|PubMed:23990668, ECO:0000269\|PubMed:25313067, ECO:0000269\|PubMed:28028151, ECO:0000269\|PubMed:9738012, ECO:0000269\|PubMed:9830023, ECO:0000269\|PubMed:9873035, ECO:0000269\|PubMed:9927633}.
Catalytic activity CATALYTIC ACTIVITY: Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-[protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.13; CATALYTIC ACTIVITY: Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060, Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216; EC=2.7.11.13; Evidence={ECO:0000269\|PubMed:25313067};
Subellular location SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269\|PubMed:23990668}. Cell membrane {ECO:0000269\|PubMed:23990668}; Peripheral membrane protein {ECO:0000305\|PubMed:23990668}. Mitochondrion membrane {ECO:0000269\|PubMed:9738012}; Peripheral membrane protein {ECO:0000305\|PubMed:9738012}. Nucleus {ECO:0000250\|UniProtKB:P20444}.
Structure SUBUNIT: Recruited in a circadian manner into a nuclear complex which also includes BMAL1 and RACK1 (By similarity). Interacts with ADAP1/CENTA1 (PubMed:12893243). Interacts with CSPG4 (PubMed:15504744). Binds to CAVIN2 in the presence of phosphatidylserine (By similarity). Interacts with PRKCABP/PICK1 (via PDZ domain) (PubMed:15247289). Interacts with TRIM41 (PubMed:17893151). Interacts with PARD3 (PubMed:27925688). Interacts with SOCS2 (By similarity). {ECO:0000250\|UniProtKB:P05696, ECO:0000250\|UniProtKB:P20444, ECO:0000269\|PubMed:12893243, ECO:0000269\|PubMed:15247289, ECO:0000269\|PubMed:15504744, ECO:0000269\|PubMed:17893151, ECO:0000269\|PubMed:27925688}.
Target Relevance information above includes information from UniProt accession : P17252
The UniProt Consortium

Data

IHC-image-anti-PKC (Protein kinase C) alpha antibody-1035_1

Detection of mouse PKC-alpha by immunohistochemistry. Sample: FFPE section of mouse retina. Antibody: Affinity purified rabbit anti-PKC-alpha (#1035) used at a dilution of 1:100 (2µg/ml). Detection: Red-fluorescent goat anti-rabbit IgG-heavy and light chain cross-adsorbed Antibody DyLight? 594 Conjugated used at a dilution of 1:100. Counterstain: DAPI (blue)

WB-image-anti-PKC (Protein kinase C) alpha antibody-1035_2

Detection of human and mouse PKC-alpha by western blot (h & m) and immunoprecipitation (h). Samples: Whole cell lysate from HeLa (5, 15 and 50 µg for WB; 1 mg for IP, 20% of IP loaded), HEK293T (T; 50 µg), and mouse NIH 3T3 (M; 50 µg) cells. Antibodies: Affinity purified rabbit anti-PKC-alpha antibody #1035 used for WB at 0.04 µg/ml (A) and 1 µg/ml (B) and used for IP at 3 µg/mg lysate. PKC-alpha was also immunoprecipitated by rabbit anti-PKC-alpha antibody, which recognizes an upstream epitope. Detection: Chemiluminescence with exposure times of 10 seconds (A) and 3 seconds (B).

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.